Inhibrx Biosciences, Inc. INBX Business Segments — Research And Development Expense, Clinical Trials
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept inhibrx:ResearchAndDevelopmentExpenseClinicalTrials.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s business segments — research and development expense, clinical trials.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s business segments — research and development expense, clinical trials?
- Inhibrx Biosciences, Inc. (INBX) reported business segments — research and development expense, clinical trials of $9.18M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s business segments — research and development expense, clinical trials changed year-over-year?
- Inhibrx Biosciences, Inc.'s business segments — research and development expense, clinical trials decreased by 30.8% year-over-year, from $13.27M to $9.18M.
- What does business segments — research and development expense, clinical trials mean?
- This metric represents the direct costs incurred for conducting clinical trials, including patient recruitment, site monitoring, and data management. It reflects the company's investment in advancing therapeutic candidates through human clinical testing phases. High expenditures in this area indicate active progression of the clinical pipeline.